Corrado Advisors’s Ocular Therapeutix OCUL Stock Holding History

Corrado Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-25,785	Closed	-$239K	–	120
2017 Q2	$239K	Sell	25,785 -7,020	-21%	-$67.9K	0.13%	95
2017 Q1	$304K	Buy	32,805 +1,785	+6%	+$14.9K	0.17%	84
2016 Q4	$260K	Buy	31,020 +18,745	+153%	+$145K	0.16%	89
2016 Q3	$84K	Buy	+12,275	New	+$74.8K	0.05%	103

Other funds holding OCUL

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Corrado Advisors's OCUL Position: Q3 2017 in Review

Corrado Advisors sold out of Ocular Therapeutix (OCUL) in Q3 2017, closing a stake of 25,785 shares — an estimated $239K sold.

Corrado Advisors first reported a position in OCUL in Q3 2016 and held it in 4 quarters. The position peaked at $304K in Q1 2017. 73 funds tracked by Wall St. Rank hold OCUL as of Q3 2017.

Corrado Advisors reported no remaining Ocular Therapeutix position as of Q3 2017 after selling out during the quarter.
Corrado Advisors sold 25,785 Ocular Therapeutix shares in Q3 2017, an estimated $239K.
Corrado Advisors first reported a position in Ocular Therapeutix in Q3 2016 and held it in 4 quarters.
Corrado Advisors's Ocular Therapeutix position peaked at $304K in Q1 2017.
73 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2017.

Based on Corrado Advisors's 13F filing for Q3 2017, filed 6 Oct 2017.